Kura Oncology, Inc. Common Stock KURA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:43:16.025Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:56:56.392135334Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:43:15.551811+00:00
Kura Oncology, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.61 | 102.6% | 17.3% | |||
| 25Δ | 6.81 | 102.4% | 15.5% | |||
| 30Δ | 7.01 | 102.2% | 13.7% | |||
| 35Δ | 7.21 | 102.0% | 11.9% | |||
| 40Δ | 7.41 | 101.8% | 10.1% | |||
| 45Δ | 7.61 | 101.6% | 8.3% | |||
| 50Δ | 7.81 | 101.4% | 6.5% | |||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | 5.83 | 334.0% | 8.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.61
- IV
- 102.6%
- B/E move
- 17.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.81
- IV
- 102.4%
- B/E move
- 15.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.01
- IV
- 102.2%
- B/E move
- 13.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.21
- IV
- 102.0%
- B/E move
- 11.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.41
- IV
- 101.8%
- B/E move
- 10.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.61
- IV
- 101.6%
- B/E move
- 8.3%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.81
- IV
- 101.4%
- B/E move
- 6.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.83
- IV
- 334.0%
- B/E move
- 8.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 165.14% | |
| 139.44% | |
| 168.85% | |
| 157.34% | |
| 174.78% | |
| 165.75% | |
| 169.81% | |
| 149.85% | |
| 128.12% | |
| 171.11% |
Biotechnology
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins…
More →KYTX
Description unavailable
More →KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →